Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchIbuprofenIbuprofen (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Ibuprofen for COVID-19: real-time meta analysis of 13 studies

@CovidAnalysis, June 2024, Version 11V11
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rinott -21% 1.21 [0.33-4.38] death 3/87 9/316 Improvement, RR [CI] Treatment Control Rinott -12% 1.12 [0.37-3.34] ventilation 4/87 13/316 Rinott -40% 1.40 [0.51-3.81] ICU 5/87 13/316 Abu Esba -170% 2.70 [0.33-22.0] death 1/40 11/357 Abu Esba 37% 0.63 [0.07-5.44] death 40 (n) 357 (n) Abu Esba -45% 1.45 [0.44-4.81] oxygen 40 (n) 357 (n) Abu Esba -18% 1.18 [0.59-2.36] hosp. 40 (n) 357 (n) Abu Esba -85% 1.85 [0.42-8.13] severe case 40 (n) 357 (n) Sobhy (DB RCT) 52% 0.48 [0.24-0.95] ICU 10/90 21/90 OT​1 Sobhy (DB RCT) 52% 0.48 [0.24-0.95] oxygen 10/90 21/90 OT​1 Sobhy (DB RCT) 26% 0.74 [0.58-0.94] hosp. time 90 (n) 90 (n) OT​1 Sobhy (DB RCT) 25% 0.75 [0.17-3.26] no recov. 3/90 4/90 OT​1 Sobhy (DB RCT) 43% 0.57 [0.25-1.29] no recov. 8/90 14/90 OT​1 Sobhy (DB RCT) 48% 0.52 [0.28-0.95] no recov. 13/90 25/90 OT​1 Sobhy (DB RCT) 41% 0.59 [0.37-0.94] no recov. 20/90 34/90 OT​1 Choi (PSM) -240% 3.40 [0.64-18.1] progression case control Samimagham -100% 2.00 [1.33-3.02] death 63 (n) 95 (n) Samimagham -428% 5.28 [1.82-15.3] severe case 14/63 4/95 Samimagham -13% 1.13 [1.02-1.25] progression 60/63 80/95 Kragholm 4% 0.96 [0.72-1.23] progression 264 (n) 3,738 (n) Wong -23% 1.23 [0.90-1.68] death population-based cohort Wong 17% 0.83 [0.56-1.25] death population-based cohort Reese (PSM) 9% 0.91 [0.62-1.35] death 5,737 (n) 5,737 (n) Reese (PSM) -303% 4.03 [3.69-4.40] severe case 5,737 (n) 5,737 (n) Drake 10% 0.90 [0.71-1.13] death n/a n/a Leal 3% 0.97 [0.94-1.00] cases n/a n/a Campbell (PSW) 0% 1.00 [0.99-1.01] death 1,814 (n) 20,311 (n) Campbell (PSW) 1% 0.99 [0.98-1.00] death 1,814 (n) 20,311 (n) Xie -12% 1.12 [0.92-1.38] hosp. population-based cohort OT​1 Xie -8% 1.08 [0.95-1.22] cases population-based cohort OT​1 Loucera 48% 0.52 [0.34-0.78] death 519 (n) 15,449 (n) Ibuprofen COVID-19 outcomes c19early.org June 2024 1 OT: comparison with other treatment Favors ibuprofen Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit